Talphera, Inc.

TLPH Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.

1.08 0.01 +0.93%
Market cap
$55.5M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
n/a
Altman Z
−20.73
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.00 — 0.00
Piotroski F-Score
1 2 4 1 4 4 3 4 — —
P/S ratio
6.66 12.02 62.73 72.99 19.52 23.82 9.26 11.69 — 113.49
Altman Z-Score
(2.71) (5.80) (3.35) (6.52) (10.17) (9.15) (13.61) (31.77) — (20.73)
Altman Z″-Score (non-manufacturers)
(5.06) (12.32) (6.27) (14.35) (23.31) (20.56) (30.43) (71.94) — (49.59)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00
Beneish M-Score
(1.19) — — — — — — — — —
P/Operating CF
(11.20) (14.40) (15.01) (11.80) (16.71) (8.39) (3.03) (2.67) — (19.85)
P/B ratio
0.00 0.00 31.73 0.00 0.00 0.00 0.75 0.75 — 2.84
Price to Tangible BV
0.00 0.00 31.73 0.00 0.00 0.00 0.75 0.75 — 2.84
EV/Sales
3.27 6.85 19.16 55.08 15.64 12.17 2.27 8.34 — 80.58
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00
EV/Operating CF
(1.93) (1.84) (1.42) (2.46) (2.20) (1.14) (0.14) (0.43) — (3.02)
EV/FCF
(1.71) (1.70) (1.38) (2.31) (2.10) (1.08) (0.13) (0.51) — (3.93)
Quick Ratio
8.45 4.54 6.66 4.89 2.47 2.53 1.51 2.08 3.35 5.35
Current Ratio
8.74 4.64 6.78 5.27 2.66 2.73 1.78 2.57 3.56 5.49
Net Debt/EBITDA
1.96 1.12 2.67 0.78 0.54 0.97 0.65 0.57 0.58 1.50
Debt/Assets
21.55% 25.28% 9.95% 27.53% 33.00% 17.72% 11.29% 0.00% 0.00% 0.00%
Debt/Equity
(4.04) (0.52) 2.82 (0.61) (0.39) (0.38) 0.25 0.00 0.00 0.00
Asset Turnover
0.15 0.09 0.02 0.02 0.07 0.04 0.03 0.02 0.00 0.00
Operating CF/Net income
0.68 0.58 0.62 0.96 0.95 0.85 (0.67) 0.95 0.98 0.80
Capex/Depreciation
(1.81) (1.38) (1.42) (2.08) (1.00) (0.93) (1.25) 9.14 0.00 0.00
Interest Coverage
(2.63) (2.76) (2.84) (45.25) 8,192.60 48.15 (22.67) (126.04) (38.71) —
ROE
(310.75%) 246.18% 292.34% 286.51% 83.11% 76.60% (601.31%) (102.44%) (117.65%) (114.16%)
ROA
(37.89%) (58.68%) (48.09%) (50.25%) (51.23%) (48.69%) 67.52% (54.20%) (67.32%) (59.60%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (246.80%) (223.45%) 0.00% 0.00%
Return on Tangible Assets
(48.18%) (84.71%) (45.53%) (73.30%) (90.02%) (73.26%) 392.08% (260.43%) (192.08%) (83.61%)
Average Days of Receivables
122.66 69.99 68.05 68.89 42.79 20.72 0.00 0.00 — 0.00
Research and Development Expense of Revenue
123.30% 242.76% 610.74% 203.63% 74.17% 145.32% 188.65% 851.92% 0.00% 21,546.43%
Selling, General and Administrative Expense of Revenue
89.86% 207.74% 965.36% 1,967.10% 670.79% 1,097.76% 960.53% 1,842.40% 0.00% 26,710.71%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
25.81% 53.71% 240.26% 220.93% 81.68% 163.56% 163.13% 265.59% 0.00% 2,496.43%
Graham Net Nets
(0.14) (0.51) (0.06) (0.37) (0.71) (0.94) (0.07) 0.50 — 0.17
Graham Number
31.57 88.20 0.00 56.16 53.15 27.96 20.72 0.00 — 0.00
Earnings Yield
(36.86%) (54.15%) (35.50%) (31.75%) (38.71%) (51.79%) 290.99% (200.00%) — (32.46%)
Free Cash Flow Yield
(28.66%) (33.47%) (22.16%) (32.71%) (38.18%) (47.42%) (185.32%) (140.87%) — (18.08%)
Revenue per Share
7.66 3.41 0.74 0.58 1.27 0.47 0.24 0.05 0.00 0.00
Operating CF per Share
(12.97) (12.70) (9.96) (12.93) (9.03) (5.01) (3.84) (1.23) (0.49) (0.27)
Capex per Share
(1.64) (1.03) (0.28) (0.88) (0.44) (0.30) (0.28) 0.18 0.00 0.00
Free Cash Flow per Share
(14.62) (13.72) (10.24) (13.80) (9.47) (5.31) (4.11) (1.04) (0.49) (0.27)
Cash per Share
35.45 25.80 36.20 16.70 10.06 7.78 2.81 0.66 0.34 0.48
Shareholders Equity per Share
(2.36) (15.57) 1.46 (10.46) (13.08) (5.99) 2.95 0.99 0.31 0.40
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(2.36) (15.57) 1.46 (10.46) (13.08) (5.99) 2.95 0.99 0.31 0.40
Free Cash Flow
(33.11) (32.17) (29.89) (54.65) (40.36) (31.83) (30.38) (14.87) (12.68) (11.36)
Working Capital
78.86 49.75 92.07 58.08 29.20 31.98 10.80 7.06 6.77 17.09
Capital Expenditures
(3.72) (2.40) (0.82) (3.47) (1.85) (1.83) (2.05) 2.62 — —
Net Current Asset Value
(16.28) (48.65) (8.29) (61.09) (75.21) (63.30) (1.11) 5.29 (0.82) 8.22
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00
Capex to Sales
0.21 0.30 0.38 1.52 0.34 0.65 1.16 (4.03) — 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00
Other line items
Depreciation/Fixed assets
0.19 0.16 0.05 0.11 0.12 0.12 0.00 0.00 0.00 0.00
Cash ROIC
(34.31%) (74.72%) (24.51%) (109.59%) (447.90%) (129.70%) (63.37%) (63.31%) (75.21%) (30.37%)
Accounts Receivable Turnover
3.81 2.17 2.22 5.50 10.15 7.09 7.55 0.00 — 0.00
Accounts Payable Turnover
7.90 7.15 2.28 3.59 2.71 1.55 0.00 0.00 0.00 0.00
Inventory Turnover
9.40 6.85 4.39 3.28 2.45 2.74 0.00 — — —
Average Days of Payables
46.18 48.76 190.03 92.24 165.62 206.28 0.00 0.00 0.00 0.00
Days of Inventory on Hand
63.84 32.74 78.40 176.71 98.39 108.05 165.95 — — —
Average Receivables
4.56 3.68 0.97 0.42 0.53 0.40 0.23 — — —
Average Payables
1.56 1.49 1.75 1.90 2.23 2.43 1.69 1.30 1.00 0.61
Average Inventory
1.31 1.56 0.91 2.07 2.46 1.37 1.14 — — —
Average Assets
113.89 87.77 98.04 105.94 78.83 72.09 62.69 33.94 19.32 23.98
Average Common Equity
13.89 (20.92) (16.13) (18.58) (48.58) (45.82) (7.04) 17.96 11.05 12.52

Fold the line items

Columns are period end dates